Compare AstraZeneca plc (AZN) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs JPMorgan Chase & Co — how do they compare? AstraZeneca plc trades at $167.12 (market cap $253.13B), while JPMorgan Chase & Co trades at $344.65 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 3.6× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | JPM | |
|---|---|---|
Market Cap | $253.13B | $911.47B |
Sector | Health | Financials |
52-Week High | $209.48 | $342.89 |
52-Week Low | $137.44 | $282.84 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | 1.75% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
JPMorgan Chase (JPM) trades at $334.53, down 0.58% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with $181.85B revenue in 2025 and net income of $57.05B, though recent earnings were mixed with a Q4 2025 miss but Q1 and Q2 2026 beats. Analyst consensus is moderately bullish with a $369.67 price target. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings as key catalysts.
JPMorgan presents a solid investment case with robust profitability (31.61% net margin, 17.03% ROE) and reasonable valuation (P/E 14.69). Risks include geopolitical tensions impacting banking operations and cybersecurity threats from advanced AI. The stock offers upside to analyst targets but faces headwinds from economic uncertainty and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
